E-DRUG: Ph.D. thesis on CEE drug markets
---------------------------------------
[Please reply direcly to Kasia. "Katarzyna Nowicka" <kno@amp.pw.edu.pl>]
Dear e-drug,
I am writting Ph.D. thesis concerning obstacles in the devolopment of Polish pharmaceutical sector. The main problems I am analysing are the nonformal barriers to access to the potential markets.
I would highly appriciate your advice on:
1. level of public sector reimbursement of prescribed drugs in:
Russia, Lithuana, Hungary, Ukraine, Czech, Belorus, Estonia, Lativa, Bulgaria, Slovenia, Slovakia
2. generics % market share in volume (and value) in:
Russia, Ukraine, Belorus, Estonia, Lativa, Bulgaria, Slovenia, Slovakia
3. VAT, retail, wholesaler and producer margins (on essential drugs) in:
Russia, Lithuana, Hungary, Ukraine, Czech, Belorus, Estonia, Lativa, Bulgaria, Slovenia, Slovakia
4. the averrage real time needed for price and reimbursement acceptance and publication those info when introducing a new drug on the following markets:
Russia, Lithuana, Hungary, Ukraine, Czech, Belorus, Estonia, Lativa, Bulgaria, Slovenia, Slovakia
5. is the generics substituion allowed in:
Russia, Ukraine, Belorus
6. are doctors required to prescribe by INN in
Russia, Ukraine, Belorus
7. are doctors encouraged to prescribe generics
Russia, Ukraine, Belorus, France
or the sources for above data (I have checked EGA & WHO info)
Thank you in advance for your help,
kind regards,
Kasia Nowicka
student
Poland
"Katarzyna Nowicka" <kno@amp.pw.edu.pl>